SALIX PHARMACEUTICALS LTD Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2012-11-07: Form 8-K; Period of report 2012-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2012-10-26: Form 8-K; Period of report 2012-10-24; Description 8.01 Other Events; Details 8.01.
- 2012-10-22: Form 8-K; Period of report 2012-10-19; Description 8.01 Other Events; Details 8.01.
- 2012-09-07: Form 8-K; Period of report 2012-09-05; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2012-11-07 | 8-K | 2012-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing its financial and operating results for the third quarter ended September 30, 2012. | d434255d8k.htm |
| 2012-10-26 | 8-K | 2012-10-24 | 8.01 Other Events | 8.01 On October 24, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing it will report third quarter 2012 financial results following the close of the U.S. financial markets on Wednesday, November 7, 2012. | d430607d8k.htm |
| 2012-10-22 | 8-K | 2012-10-19 | 8.01 Other Events | 8.01 On October 19, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing that educational activities and numerous presentations describing the investigation of several of the Company’s products will occur during the American College of Gastroenterology (ACG) 2012 Annual Scientific Meeting. | d426145d8k.htm |
| 2012-09-07 | 8-K | 2012-09-05 | 8.01 Other Events | 8.01 On September 5, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing that the Food and Drug Administration advised the Company that its New Drug Application for crofelemer 125 mg tablets is still under review and that a final action will not be taken by the scheduled Prescription Drug User Fee Act goal date of September 5, 2012. | d408326d8k.htm |
| 2012-08-10 | 8-K | 2012-08-08 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On August 6, 2012, Salix Pharmaceuticals, Inc., a wholly-owned subsidiary of Salix Pharmaceuticals, Ltd., and Alfa Wassermann S.p.A. entered into an Amended and Restated License Agreement to restructure their arrangements for the exploitation of rifaximin products. 8.01 On August 8, 2012, Salix issued a press release announcing its entry into the Amended and Restated License Agreement and related agreements. | d394679d8k.htm |
| 2012-08-08 | 8-K | 2012-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing its financial and operating results for the second quarter ended June 30, 2012. | d393277d8k.htm |
| 2012-07-31 | 8-K | 2012-07-25 | 8.01 Other Events | 8.01 On July 25, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing it will report second quarter 2012 financial results following the close of the U.S. financial markets on Wednesday, August 8, 2012. | d388739d8k.htm |
| 2012-06-20 | 8-K | 2012-06-14 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The 2012 annual meeting of stockholders for Salix Pharmaceuticals, Ltd. was held on June 14, 2012. | d369431d8k.htm |
| 2012-05-31 | 8-K | 2012-05-29 | 8.01 Other Events | 8.01 On May 29, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing that the Company will present at three investment conferences during June 2012. | d361203d8k.htm |
| 2012-05-16 | 8-K | 2012-05-14 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 The Board of Directors of Salix Pharmaceuticals, Ltd. (the “Company”) has approved an amendment to the Company’s 2005 Stock Plan (the “Plan”) to clarify the Plan’s prohibition in Section 15(b) on option repricing without stockholder approval. | d353806d8k.htm |
| 2012-05-07 | 8-K | 2012-05-07 | 2.02 Results of Operations and Financial Condition | 2.02 On May 7, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing its operating results for the first quarter ended March 31, 2012. | d347907d8k.htm |
| 2012-05-02 | 8-K | 2012-04-25 | 8.01 Other Events | 8.01 On April 25, 2012, Salix Pharmaceuticals, Ltd. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (FDA) extended its review of the Company’s Supplemental New Drug Application (sNDA) for RELISTOR® for the proposed treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain until July 27, 2012. | d343222d8k.htm |
| 2012-04-24 | 8-K | 2012-04-23 | 8.01 Other Events | 8.01 On April 23, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing it will report first quarter 2012 financial results following the close of the U.S. financial markets on Monday, May 7, 2012. | d339024d8k.htm |
| 2012-03-16 | 8-K | 2012-03-13 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Definitive Material Agreement. 2.03 The information set forth under the heading “Indenture” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 3.02 The information regarding the warrants discussed under the heading “Convertible Note Hedge and Warrant Transactions” in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. 8.01 Concurrent with the closing of the issuance and sale of the Notes due 2019, Salix repurchased approximately $75,000,000 of shares of its common stock. | d316067d8k.htm |
| 2012-03-13 | 8-K | 2012-03-13 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 Entry into a Definitive Material Agreement. 7.01 On March 13, 2012, Salix issued a press release announcing the pricing of its convertible senior notes to be sold to institutional investors. 8.01 A provision in the indenture governing Salix’s 5.5% Convertible Senior Notes due 2028 prohibits Salix or any of its subsidiaries from incurring any additional indebtedness, other than permitted debt, as defined in the indenture. | d314826d8k.htm |
| 2012-03-12 | 8-K | 2012-03-12 | 7.01 Regulation FD Disclosure | 7.01 On March 12, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing its intention to offer convertible senior notes to institutional investors. | d314331d8k.htm |
| 2012-03-02 | 8-K | 2012-02-28 | 8.01 Other Events | 8.01 On February 28, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing that the Company will present at the Cowen and Company 32nd Annual Health Care Conference in Boston, Massachusetts on Tuesday, March 6, 2012 at 10:40 a.m., Eastern Time. | d308624d8k.htm |
| 2012-02-28 | 8-K/A | 2011-12-20 | 9.01 Financial Statements and Exhibits | 9.01 • Audited Consolidated Balance Sheets as of December 31, 2010 and 2009. | d306326d8ka.htm |
| 2012-02-27 | 8-K | 2012-02-27 | 2.02 Results of Operations and Financial Condition | 2.02 On February 27, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing financial and operating results for the fourth quarter and full year ended December 31, 2011 and other business updates. | d307345d8k.htm |
| 2012-02-22 | 8-K | 2012-02-21 | 8.01 Other Events | 8.01 On February 21, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing initiation of a Phase 3 study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg in subjects with Irritable Bowel Syndrome with diarrhea. | d304261d8k.htm |
| 2012-02-14 | 8-K | 2012-02-13 | 8.01 Other Events | 8.01 On February 13, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing it will report fourth quarter 2011 and full year 2011 financial results following the close of the U.S. financial markets on Monday, February 27, 2012. | d300738d8k.htm |
| 2012-02-10 | 8-K | 2012-02-07 | 8.01 Other Events | 8.01 On February 7, 2012, Salix issued a press release announcing that the U.S. Food and Drug Administration granted a priority review classification with a Prescription Drug User Fee Act (PDUFA) date of June 5, 2012 for the Company’s New Drug Application for Crofelemer for the proposed treatment of HIV-associated diarrhea. | d298064d8k.htm |
| 2012-01-05 | 8-K | 2012-01-04 | 8.01 Other Events | 8.01 On January 4, 2012, Salix issued a press release announcing that the Company will present at The 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 11, 2012 at 4:30 p.m. | d277902d8k.htm |